These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28925030)
1. Drug repurposing may generate novel approaches to treating depression. Ebada ME J Pharm Pharmacol; 2017 Nov; 69(11):1428-1436. PubMed ID: 28925030 [TBL] [Abstract][Full Text] [Related]
2. Glutamate-Based Drug Discovery for Novel Antidepressants. Pałucha-Poniewiera A; Pilc A Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299 [TBL] [Abstract][Full Text] [Related]
3. Repurposing Marketed Drugs as Antidepressants with In Silico, In Vivo, and In Vitro Screening Methods. Naveena P; Usha KK; Swetha M; Hemalatha M; Swathi K Adv Exp Med Biol; 2023; 1423():271-278. PubMed ID: 37525054 [TBL] [Abstract][Full Text] [Related]
5. Targeting glutamate signalling in depression: progress and prospects. Murrough JW; Abdallah CG; Mathew SJ Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025 [TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for major depressive disorder. Connolly KR; Thase ME Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643 [TBL] [Abstract][Full Text] [Related]
7. Exploring the potential of drug repurposing for treating depression. Verma C; Jain K; Saini A; Mani I; Singh V Prog Mol Biol Transl Sci; 2024; 207():79-105. PubMed ID: 38942546 [TBL] [Abstract][Full Text] [Related]
8. The influence of ketamine on drug discovery in depression. Kraus C; Wasserman D; Henter ID; Acevedo-Diaz E; Kadriu B; Zarate CA Drug Discov Today; 2019 Oct; 24(10):2033-2043. PubMed ID: 31382015 [TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant. Pešić V; Petrović J; M Jukić M Drug Dev Res; 2016 Nov; 77(7):414-422. PubMed ID: 27546787 [TBL] [Abstract][Full Text] [Related]
10. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Gerhard DM; Wohleb ES; Duman RS Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424 [TBL] [Abstract][Full Text] [Related]
11. Repurposing antidepressants for anticancer drug discovery. Song Y; Yang X; Yu B Drug Discov Today; 2022 Jul; 27(7):1924-1935. PubMed ID: 34728374 [TBL] [Abstract][Full Text] [Related]
12. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Nguyen L; Matsumoto RR Behav Brain Res; 2015 Dec; 295():26-34. PubMed ID: 25804358 [TBL] [Abstract][Full Text] [Related]
13. Animal inflammation-based models of depression and their application to drug discovery. Ma L; Demin KA; Kolesnikova TO; Khatsko SL; Zhu X; Yuan X; Song C; Meshalkina DA; Leonard BE; Tian L; Kalueff AV Expert Opin Drug Discov; 2017 Oct; 12(10):995-1009. PubMed ID: 28816544 [TBL] [Abstract][Full Text] [Related]
14. On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Millan MJ Int J Neuropsychopharmacol; 2014 Jul; 17(7):1009-37. PubMed ID: 23719026 [TBL] [Abstract][Full Text] [Related]
15. Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders. Sun Y; Narayan VA; Wittenberg GM BMC Pharmacol Toxicol; 2016 Oct; 17(1):47. PubMed ID: 27765060 [TBL] [Abstract][Full Text] [Related]
16. Ketamine: repurposing and redefining a multifaceted drug. Potter DE; Choudhury M Drug Discov Today; 2014 Dec; 19(12):1848-54. PubMed ID: 25224017 [TBL] [Abstract][Full Text] [Related]